本頁面由Tiger Trade Technology Pte. Ltd.提供服務

PROTEOMICS INTERNATIONAL LAB

0.355
-0.010-2.74%
成交量:30.24萬
成交額:10.91萬
市值:5,861.63萬
市盈率:-5.87
高:0.382
開:0.365
低:0.350
收:0.365
52周最高:0.860
52周最低:0.285
股本:1.65億
流通股本:1.22億
量比:1.05
換手率:0.25%
股息:- -
股息率:- -
每股收益(TTM):-0.060
每股收益(LYR):-0.060
淨資產收益率:-73.41%
總資產收益率:-40.28%
市淨率:4.45
市盈率(LYR):-5.87

資料載入中...

公司資料

公司名字:
PROTEOMICS INTERNATIONAL LAB
交易所:
ASX
成立時間:
2001
員工人數:
- -
公司地址:
QEII Medical Centre,QQ Block,6 Verdun Street,Nedlands,Perth,Western Australia,Australia
郵編:
6009
傳真:
- -
簡介:
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis and giardia. The company also offers analytical services, including specialist contract research, analytical, and consultancy. Proteomics International Laboratories Ltd has a research agreement with the Busselton Population Medical Research Institute to enhance diagnosis and treatment of lung conditions, such as asthma and chronic obstructive pulmonary disease; and the Janssen Research & Development, LLC for the research of diabetic kidney and heart disease treatment. The company was founded in 2001 and is based in Perth, Australia.